108 related articles for article (PubMed ID: 21525754)
21. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.
Söderberg C; Stål P; Askling J; Glaumann H; Lindberg G; Marmur J; Hultcrantz R
Hepatology; 2010 Feb; 51(2):595-602. PubMed ID: 20014114
[TBL] [Abstract][Full Text] [Related]
22. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
23. ASH and NASH.
Scaglioni F; Ciccia S; Marino M; Bedogni G; Bellentani S
Dig Dis; 2011; 29(2):202-10. PubMed ID: 21734385
[TBL] [Abstract][Full Text] [Related]
24. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
Weiner RA
Dig Dis; 2010; 28(1):274-9. PubMed ID: 20460923
[TBL] [Abstract][Full Text] [Related]
25. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study.
Chang Y; Ryu S; Sung KC; Cho YK; Sung E; Kim HN; Jung HS; Yun KE; Ahn J; Shin H; Wild SH; Byrne CD
Gut; 2019 Sep; 68(9):1667-1675. PubMed ID: 30472683
[TBL] [Abstract][Full Text] [Related]
26. Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease.
Rakha EA; Adamson L; Bell E; Neal K; Ryder SD; Kaye PV; Aithal GP
J Clin Pathol; 2010 Sep; 63(9):790-5. PubMed ID: 20819880
[TBL] [Abstract][Full Text] [Related]
27. Synergy between NAFLD and AFLD and potential biomarkers.
Lakshman R; Shah R; Reyes-Gordillo K; Varatharajalu R
Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1():S29-34. PubMed ID: 26189985
[TBL] [Abstract][Full Text] [Related]
28. Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study.
Chang Y; Cho YK; Cho J; Jung HS; Yun KE; Ahn J; Sohn CI; Shin H; Ryu S
Am J Gastroenterol; 2019 Apr; 114(4):620-629. PubMed ID: 30694866
[TBL] [Abstract][Full Text] [Related]
29. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.
Kim H; Lee K; Lee KW; Yi NJ; Lee HW; Hong G; Choi Y; You T; Suh SW; Jang JJ; Suh KS
Clin Transplant; 2014 May; 28(5):521-9. PubMed ID: 24579874
[TBL] [Abstract][Full Text] [Related]
30. Patients with early-stage alcohol-associated liver disease are at increased risk of hospital readmission and death.
Aryan M; Qian S; Chen Z; Louissaint J; Qian X; Rosenblatt R; Verna E; Brown R; Wong R; Clark V; Zhang W
Eur J Gastroenterol Hepatol; 2024 Mar; 36(3):318-325. PubMed ID: 38179871
[TBL] [Abstract][Full Text] [Related]
31. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).
Fernández Rodríguez CM; Aller R; Gutiérrez García ML; Ampuero J; Gómez-Camarero J; Martín-Mateos RMª; Burgos-Santamaría D; Rosales JM; Aspichueta P; Buque X; Latorre M; Andrade RJ; Hernández-Guerra M; Romero-Gómez M
Rev Esp Enferm Dig; 2019 Apr; 111(4):264-269. PubMed ID: 30810330
[TBL] [Abstract][Full Text] [Related]
32. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of patients with NAFLD and elevated liver enzymes.
Ekstedt M; Franzén LE; Mathiesen UL; Thorelius L; Holmqvist M; Bodemar G; Kechagias S
Hepatology; 2006 Oct; 44(4):865-73. PubMed ID: 17006923
[TBL] [Abstract][Full Text] [Related]
34. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
35. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
36. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.
Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
Clin Gastroenterol Hepatol; 2019 May; 17(6):1148-1156.e4. PubMed ID: 30471458
[TBL] [Abstract][Full Text] [Related]
37. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States.
Golabi P; Paik J; Reddy R; Bugianesi E; Trimble G; Younossi ZM
BMC Gastroenterol; 2019 Apr; 19(1):56. PubMed ID: 30991959
[TBL] [Abstract][Full Text] [Related]
39. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Brown GT; Kleiner DE
Metabolism; 2016 Aug; 65(8):1080-6. PubMed ID: 26775559
[TBL] [Abstract][Full Text] [Related]
40. Impact of metabolic risk factors on hepatic and cardiac outcomes in patients with alcohol- and non-alcohol-related fatty liver disease.
Lim J; Sang H; Kim HI
JHEP Rep; 2023 Jun; 5(6):100721. PubMed ID: 37138675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
